Retracted: Optimising ▼ Enfortumab
Vedotin + Pembrolizumab in
Comorbid
Patients with Unresectable or Metastatic Urothelial Carcinoma
This publication is intended for healthcare professionals only and has been commissioned and funded by Astellas Pharma Ltd.
Support: The publication of this article has been supported by Astellas Pharma Ltd.
Author: Nick Ellis1
1. Oncology Astellas Pharma Ltd, UK *Correspondence to nick_ellis@astellas.com
Contributors: Giuseppe Fornarini,2 Carole Helissey,3 Robert Jones,4 Vadim Koshkin,5 Dora Niedersüß-Beke,6 Javier Puente,7 Michiel Simon van der Heijden,8 Gunhild von Amsberg9
2. IRCCS Policlinico San Martino Genova, Italy
3. Clinical Research Unit, HIA BEGIN, Department of Radiation Biological Effects, French Armed Forces Biomedical Research Institute, Brétignysur-Orge, France
4. Beatson West of Scotland Cancer Centre, Glasgow, UK
5. University of California, San Francisco, USA
6. Center for Oncology, Hematology and Palliative Medicine, Wilhelminenspital Montleartstraße, Vienna, Austria
7. Hospital Clinico Universitario San Carlos, Madrid, Spain
8. Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands
9. Martini Clinic University Medical Center, Hamburg, Germany
Disclosure: All contributors have received honoraria from Astellas Pharma Ltd and have declared no conflicts of interest.
Acknowledgements:
Medical writing and editorial support were provided by OPEN Health Medical Communications, London, UK, and funded by Astellas Pharma Ltd, in accordance with Good Publication Practice (GPP) guidelines.
Disclaimer: Astellas Pharma Ltd also had editorial input in the writing of this publication. The publisher retained final editorial control of the content. The opinions expressed are not necessarily those of the publisher.
Date of preparation: September 2025 | MAT-GB-PAD-2025-00234
Prescribing information for PADCEVTM▼(enfortumab vedotin) is available at the end of this article.
Indication: PADCEVTM (enfortumab vedotin), in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinumcontaining chemotherapy.
PADCEVTM (enfortumab vedotin) as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
▼This medicinal product is subject to additional monitoring.
Received: 01.07.25
Accepted: 07.08.25
Keywords: Comorbidity, enfortumab vedotin (EV), frail, guidance, management, metastatic urothelial carcinoma (mUC), pembrolizumab.
Citation: EMJ Oncol. 2025;13[Suppl 2]:2-14. https://doi.org/10.33590/emjoncol/IVMM2109
Editorial Note: This article, originally published on 05.09.2025, was temporarily removed for further review at Astellas' request on 25.09.2025. It was reviewed and republished with updated PI/AER information on 25.09.2025.
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published. Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published. Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published. Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published. Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published. Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
This article has now been retracted and a retraction statement has been published.
Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma